| |
|
Global Hepatitis Summit - Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients With Metabolic Syndrome and HCV Infection: An Integrated Analysis
|
| |
| |
Reported by Jules Levin
16th Annual International Symposium on Viral Hepatitis and Liver Disease's Global Hepatitis Summit, 14-17 June 2018, Toronto, Canada
Alessio Aghemo1, Axel Baumgarten2, Victor de Ledinghen3, Ira Jacobson4, Samuel S Lee5, Sammy Saab6, Henning Kleine7, Eric D Crown8, Antonella De Michina9, Yang Lei8, Christi ne Collins8, Antonio Craxi10
1Humanitas Clinical and Research Center, Milan, Italy; 2Center for Infecti ology, Berlin, Germany; 3Centre d'Investi gati on de la Fibrose Hepati que, Hopital Haut-Leveque, Centre Hospitalier Universitaire de Bordeaux, Pessac, France; INSERM U1053, Universite Bordeaux, Bordeaux, France; 4NYU School of Medicine, New York, New York, United States; 5University of Calgary, Calgary, Alberta, Canada; 6David Geff en School of Medicine at the University of California at Los Angeles, Los Angeles, California, United States; 7AbbVie Deutschland GmbH & Co., KG, Wiesbaden, Germany; 8AbbVie Inc., North Chicago, Illinois, United States; 9AbbVie srl, Rome, Italy; 10Sezione di Gastroenterologia ed Epatologia, DIBIMIS, University of Palermo, Italy
| |
| |
| |
|
|
|
